JANUVIA®

(sitagliptin) 25 mg, 50 mg, 100 mg tablets

Efficacy Profile

JANUVIA head-to-head vs sulfonylurea


As an adjunct to diet and exercise for appropriate adult patients with type 2 diabetes

JANUVIA + metformin: Strong A1C lowering similar to glipizide + metformin1

Primary end point: A1C reductions vs glipizide at week 52a

A1C Data for JANUVIA® (sitagliptin) + Metformin vs Glipizide + Metformin

Week 52 results for patients uncontrolled on metformin ≥1500 mg/day (per protocol population).

(a) Per-protocol analysis: Per-protocol population included patients without major protocol violations who had observations at baseline and week 52. Glipizide 5 to 20 mg/day (mean dose: 10.3 mg/day).

LS = least squares.

  • In the intent-to-treat population, patients treated with JANUVIA 100 mg once daily + metformin ≥1500 mg/day (n=576) achieved LS mean A1C reductions from baseline comparable with glipizide 5 to 20 mg/day (mean dose: 10.6 mg/day) + metformin ≥1500 mg/day (n=559): JANUVIA –0.5% (mean baseline A1C 7.7%); glipizide –0.6% (mean baseline A1C 7.6%).
  • A conclusion in favor of the noninferiority of JANUVIA to glipizide may be limited to patients with baseline A1C comparable to those included in the study (>70% of patients had baseline A1C <8% and >90% had A1C <9%).

Study design

52-week study evaluating sitagliptin vs glipizide in patients uncontrolled on metformin alone: A multinational, randomized, double-blind, parallel-group, noninferiority study was conducted in 1,172 patients with type 2 diabetes who were 18 to 78 years of age and were inadequately controlled on metformin (A1C ≥6.5%–≤10%). Patients on a stable dose of metformin (≥1500 mg/day) were randomized to receive sitagliptin 100 mg once daily (n=588) or glipizide 5 mg/day (n=584) in addition to metformin. Based on glycemic control, glipizide could be titrated to a maximum dose of 20 mg/day. The efficacy and safety of sitagliptin were compared with glipizide over 52 weeks.1

Indication

JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JANUVIA should not be used in patients with type 1 diabetes.

JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

Selected Safety Information

JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.

There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiating JANUVIA, observe patients carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

An association between dipeptidyl peptidase-4 (DPP-4) inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Consider the risks and benefits of JANUVIA prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy. Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of JANUVIA.

There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. A subset of these reports involved patients with renal impairment, some of whom were prescribed inappropriate doses of sitagliptin.

Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. A dosage adjustment is recommended in patients with moderate or severe renal impairment and in patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis.

When JANUVIA was used in combination with insulin or insulin secretagogues (eg, sulfonylurea), medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia.

The incidence (and rate) of hypoglycemia based on all reports of symptomatic hypoglycemia were: 12.2% (0.59 episodes/patient-year) for JANUVIA 100 mg in combination with glimepiride (with or without metformin), 1.8% (0.24 episodes/patient-year) for placebo in combination with glimepiride (with or without metformin), 15.5% (1.06 episodes/patient-year) for JANUVIA 100 mg in combination with insulin (with or without metformin), and 7.8% (0.51 episodes/patient-year) for placebo in combination with insulin (with or without metformin).

There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes.

Angioedema has also been reported with other DPP-4 inhibitors. Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUVIA.

There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from 1 day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.

Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving JANUVIA. If bullous pemphigoid is suspected, JANUVIA should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.

In clinical studies, the adverse reactions reported, regardless of investigator assessment of causality, in ≥5% of patients treated with JANUVIA as monotherapy and in combination therapy and more commonly than in patients treated with placebo, were upper respiratory tract infection, nasopharyngitis, and headache.

Before prescribing JANUVIA® (sitagliptin) tablets, please read the accompanying Prescribing Information. The Medication Guide also is available.

Reference

1. Nauck MA, Meininger G, Sheng D, et al; for Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205.

US-DIA-0223410/21